Skip to main navigation
Neurogene Inc.
Toggle Menu
  • Home
  • About Us
    • Our Leadership
    • A Message from Our Founder
  • Our Technology
    • Gene Therapy Platform
    • Manufacturing
    • Partnerships
  • Our Pipeline
    • About Rett Syndrome
    • About NGN-401
    • Rett Syndrome Clinical Program
    • Other Programs
    • Expanded Access Policy
    • Publications
  • Patients & Families
    • Our Approach
    • What is Rett Syndrome?
    • Rett Syndrome Resources
    • Rett Syndrome Clinical Program
    • Thank You
    • Patient Advocacy & Engagement at Neurogene
    • Communication Corner
    • Rare Disease Community Resources
  • Investors
  • Careers
    • Life at Neurogene
    • Open Positions
    • Benefits

Event Details

decorative diamond pattern
  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
  • Corporate Governance
    • Governance Overview
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial Information
    • SEC Filings
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Shareholder Services
    • Investor FAQs
    • Email Alerts
    • RSS Feeds
    • Investor Contacts

NGN-401 Phase 1/2 Clinical Data Update

June 29, 2026 8:00 AM EDT

Listen to webcast

Supporting Materials

NGN-401 Phase 1/2 Clinical Data Update June 2026 2 MB
Neurogene Inc.
  • About Us
  • Our Technology
  • Our Pipeline
  • Patients & Families
  • Investors
  • Careers
© 2026 Neurogene Inc. All Rights Reserved. Theme by SiteOrigin
Privacy  |  Terms of Use  |  Contact Us
Facebook   Linkedin   X
Scroll to top